A detailed history of Rhumbline Advisers transactions in Genmab A/S stock. As of the latest transaction made, Rhumbline Advisers holds 18,854 shares of GMAB stock, worth $389,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,854
Previous 18,694 0.86%
Holding current value
$389,335
Previous $469,000 2.13%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.84 - $28.48 $3,814 - $4,556
160 Added 0.86%
18,854 $459,000
Q2 2024

Aug 01, 2024

BUY
$25.13 - $30.27 $31,060 - $37,413
1,236 Added 7.08%
18,694 $469,000
Q1 2024

May 09, 2024

BUY
$26.43 - $32.77 $42,340 - $52,497
1,602 Added 10.1%
17,458 $522,000
Q4 2023

Feb 08, 2024

SELL
$27.94 - $35.44 $10,756 - $13,644
-385 Reduced 2.37%
15,856 $504,000
Q3 2023

Nov 09, 2023

BUY
$35.27 - $42.24 $10,968 - $13,136
311 Added 1.95%
16,241 $572,000
Q2 2023

Aug 08, 2023

BUY
$37.4 - $42.94 $595,782 - $684,034
15,930 New
15,930 $605,000
Q1 2021

May 06, 2021

SELL
$30.92 - $44.4 $175,532 - $252,058
-5,677 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$33.66 - $40.76 $191,087 - $231,394
5,677 New
5,677 $231,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.